tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2024-14-3s1-14-18tumors-1342Research ArticleСтатьиРедкие опухоли. Метастатический рак носоглоткиhttps://orcid.org/0000-0003-4879-2687БолотинаЛ. В.

Лариса Владимировна Болотина

125284 Москва, 2-й Боткинский пр-д., 3

lbolotina@yandex.ruМосковский научно-исследовательский онкологический институт им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава РоссииRussian Federation202418112024143s11418Copyright © Болотина Л.В., 20242024Болотина Л.В.Болотина Л.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1342

Рак носоглотки (РН) является уникальной патологией, для которой характерна специфическая эндемичность, половые и возрастные особенности распределения, а также высокая чувствительность к консервативным методам лечения. Одной из особенностей РН является высокая ассоциация с вирусом Эпштейна-Барр (ВЭБ), что определяет особенность функционирования сигнальных путей и высокую иммуногенность опухоли.

Статья посвящена анализу исследований химио-иммунотерапии в 1 линии лечения рецидивного / метастатического РН. 

рак носоглоткивирус Эпштейна-Баррхимио-иммунотерапияReferencesBray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–263. https://doi.org/10.3322/caac.21834Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–263. https://doi.org/10.3322/caac.21834Chua M.L.K., Wee J.T.S., Hui E.P., Chan A.T.C. Nasopharyngeal carcinoma. Lancet 2016;387(10022):1012–1024. https://doi.org/10.1016/S0140-6736(15)00055-0Chua M.L.K., Wee J.T.S., Hui E.P., Chan A.T.C. Nasopharyngeal carcinoma. Lancet 2016;387(10022):1012–1024. https://doi.org/10.1016/S0140-6736(15)00055-0Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинскиого, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена-филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России, 2016.250 с.Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинскиого, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена-филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России, 2016.250 с.Bej J.X., Jia W.H., Zeng Y.X. Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma. Semin Cancer Biol 2012;22(2):96–106. https://doi.org/10.1016/j.semcancer.2012.01.012Bej J.X., Jia W.H., Zeng Y.X. Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma. Semin Cancer Biol 2012;22(2):96–106. https://doi.org/10.1016/j.semcancer.2012.01.012Lu S.J., Day N.E., Degos L., et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 1990;346(6283):470–471. https://doi.org/10.1038/346470a0Lu S.J., Day N.E., Degos L., et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 1990;346(6283):470–471. https://doi.org/10.1038/346470a0Dai W., Zheng H., Cheung A.K.L., et al. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. Proc Natl Acad Sci USA 2016;113(12):3317–3322. https://doi.org/10.1073/pnas.1523436113Dai W., Zheng H., Cheung A.K.L., et al. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. Proc Natl Acad Sci USA 2016;113(12):3317–3322. https://doi.org/10.1073/pnas.1523436113Yu G., Hsu W.L., Coghill A.E., et al. Whole-exome sequencing of nasopharyngeal carcinoma families reveals novel variants potentially involved in nasopharyngeal carcinoma Sci Rep 2019;9(1):9916. https://doi.org/10.1038/s41598-019-46137-4Yu G., Hsu W.L., Coghill A.E., et al. Whole-exome sequencing of nasopharyngeal carcinoma families reveals novel variants potentially involved in nasopharyngeal carcinoma Sci Rep 2019;9(1):9916. https://doi.org/10.1038/s41598-019-46137-4Lo E.J., Bell D., Woo J.S., et al. Human papillomavirus and WHO type I naso- pharyngeal carcinoma. Laryngoscope 2010;120(10):1990–1997. https://doi.org/10.1002/lary.21089Lo E.J., Bell D., Woo J.S., et al. Human papillomavirus and WHO type I naso- pharyngeal carcinoma. Laryngoscope 2010;120(10):1990–1997. https://doi.org/10.1002/lary.21089Maxwell J.H., Kumar B., Feng F.Y., et al. HPV-positive/p16-positive/EBV- negative nasopharyngeal carcinoma in white North Americans. Head Neck 2010;32(5):562–567. https://doi.org/10.1002/hed.21216Maxwell J.H., Kumar B., Feng F.Y., et al. HPV-positive/p16-positive/EBV- negative nasopharyngeal carcinoma in white North Americans. Head Neck 2010;32(5):562–567. https://doi.org/10.1002/hed.21216Chan Y.H., Lo C.M., Lau H.Y., Lam T.H. Vertically transmitted nasopharyngeal infection of the human papillomavirus: Does it play an aetiological role in nasopharyngeal cancer? Oral Oncol 2014;50(5):326–329. https://doi.org/10.1016/j.oraloncology.2013.12.025Chan Y.H., Lo C.M., Lau H.Y., Lam T.H. Vertically transmitted nasopharyngeal infection of the human papillomavirus: Does it play an aetiological role in nasopharyngeal cancer? Oral Oncol 2014;50(5):326–329. https://doi.org/10.1016/j.oraloncology.2013.12.025Dogan S., Hedberg M.L., Ferris R.L., et al. Human papillomavirus and Epstein- Barr virus in nasopharyngeal carcinoma in a low- incidence population. Head Neck 2014;36(4):511–516. https://doi.org/10.1002/hed.23318Dogan S., Hedberg M.L., Ferris R.L., et al. Human papillomavirus and Epstein- Barr virus in nasopharyngeal carcinoma in a low- incidence population. Head Neck 2014;36(4):511–516. https://doi.org/10.1002/hed.23318Stenmark M.H., McHugh J.B., Schipper M., et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 2014;88(3):580–588. https://doi.org/10.1016/j.ijrobp.2013.11.246Stenmark M.H., McHugh J.B., Schipper M., et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 2014;88(3):580–588. https://doi.org/10.1016/j.ijrobp.2013.11.246Chan K.C.A., Woo J.K.S., King A., et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 2017;377(6):513–522. https://doi.org/10.1056/NEJMoa1701717Chan K.C.A., Woo J.K.S., King A., et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 2017;377(6):513–522. https://doi.org/10.1056/NEJMoa1701717Feng M., Wang W., Fan Z., et al. Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Radiat Oncol 2013;8:208. https://doi.org/10.1186/1748-717X-8-208Feng M., Wang W., Fan Z., et al. Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Radiat Oncol 2013;8:208. https://doi.org/10.1186/1748-717X-8-208He Y.X., Wang Y., Cao P.F., et al. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. Chin J Cancer 2016;35(1):96. https://doi.org/10.1186/s40880-016-0159-2He Y.X., Wang Y., Cao P.F., et al. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. Chin J Cancer 2016;35(1):96. https://doi.org/10.1186/s40880-016-0159-2Huang C.L., Chen Y., Guo R., et al. Prognostic value of MRI-determined cervical lymph node size in nasopharyngeal carcinoma. Cancer Med 2020;9(19):7100–7106. https://doi.org/10.1002/cam4.3392Huang C.L., Chen Y., Guo R., et al. Prognostic value of MRI-determined cervical lymph node size in nasopharyngeal carcinoma. Cancer Med 2020;9(19):7100–7106. https://doi.org/10.1002/cam4.3392Lin J.C., Liang W.M., Jan J.S., et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma – is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 2004;60(1):156–164. https://doi.org/10.1016/j.ijrobp.2004.03.002Lin J.C., Liang W.M., Jan J.S., et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma – is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 2004;60(1):156–164. https://doi.org/10.1016/j.ijrobp.2004.03.002Tang L.Q., Li C.F., Li J., et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst 2015;108(1):djv291. https://doi.org/10.1093/jnci/djv291Tang L.Q., Li C.F., Li J., et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst 2015;108(1):djv291. https://doi.org/10.1093/jnci/djv291Li Y.Y., Chung G.T.Y., Lui V.W.Y., et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun 2017;8:14121. https://doi.org/10.1038/ncomms14121Li Y.Y., Chung G.T.Y., Lui V.W.Y., et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun 2017;8:14121. https://doi.org/10.1038/ncomms14121Lin D.C., Meng X., Hazawa M., et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet 2014;46(8):866–871. https://doi.org/10.1038/ng.3006Lin D.C., Meng X., Hazawa M., et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet 2014;46(8):866–871. https://doi.org/10.1038/ng.3006Wong K.C.W., Hui E.P., Lo K.W., et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021;18(11):679–695. https://doi.org/10.1038/s41571-021-00524-xWong K.C.W., Hui E.P., Lo K.W., et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021;18(11):679–695. https://doi.org/10.1038/s41571-021-00524-xTsang C.M., Lui V.W.Y., Bruce J.P., et al. Translational genomics of nasopharyngeal cancer. Semin Cancer Biol 2020;61:84–100. https://doi.org/10.1016/j.semcancer.2019.09.006Tsang C.M., Lui V.W.Y., Bruce J.P., et al. Translational genomics of nasopharyngeal cancer. Semin Cancer Biol 2020;61:84–100. https://doi.org/10.1016/j.semcancer.2019.09.006Bruce J.P., To K.F., Lui V.W.Y., et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape. Nat Commun 2021;12(1):4193. https://doi.org/10.1038/s41467-021-24348-6Bruce J.P., To K.F., Lui V.W.Y., et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape. Nat Commun 2021;12(1):4193. https://doi.org/10.1038/s41467-021-24348-6Lili L., Zhang Y., Fan Y., et al. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics 2015;7(2):155–173. https://doi.org/10.2217/epi.14.79Lili L., Zhang Y., Fan Y., et al. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics 2015;7(2):155–173. https://doi.org/10.2217/epi.14.79Fang W., Zhang J., Honget S., et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014;5(23):12189–12202. https://doi.org/10.18632/oncotarget.2608Fang W., Zhang J., Honget S., et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014;5(23):12189–12202. https://doi.org/10.18632/oncotarget.2608Outh-Gauer S., Alt M., Le Tourneau C., et al. Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians. Cancer Treat. Rev 2018;65:54–64. https://doi.org/10.1016/j.ctrv.2018.02.008Outh-Gauer S., Alt M., Le Tourneau C., et al. Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians. Cancer Treat. Rev 2018;65:54–64. https://doi.org/10.1016/j.ctrv.2018.02.008Li Y.F., Ding J.W., Liao L.M., et al. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol 2017;7(3):378–382. https://doi.org/10.3892/mco.2017.1318Li Y.F., Ding J.W., Liao L.M., et al. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol 2017;7(3):378–382. https://doi.org/10.3892/mco.2017.1318Yang Y., Pan J., Wand H., et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell 2023;41(6):1061–1072.e4. https://doi.org/10.1016/j.ccell.2023.04.014Yang Y., Pan J., Wand H., et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell 2023;41(6):1061–1072.e4. https://doi.org/10.1016/j.ccell.2023.04.014Mai H.Q., Chen Q.Y., Chen D., et al. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA 2023;330(20):1961–1970. https://doi.org/10.1001/jama.2023.20181Mai H.Q., Chen Q.Y., Chen D., et al. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA 2023;330(20):1961–1970. https://doi.org/10.1001/jama.2023.20181Yang Y., Qu S., Li J., et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021;22(8):1162–1174. https://doi.org/10.1016/S1470-2045(21)00302-8Yang Y., Qu S., Li J., et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021;22(8):1162–1174. https://doi.org/10.1016/S1470-2045(21)00302-8Huang J., Xu J., Chen Y., et al. Camrelizumab versus investigator‘s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2020:21(6):832–842. https: //doi.org/10.1016/S1470–2045(20)30110–8Huang J., Xu J., Chen Y., et al. Camrelizumab versus investigator‘s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2020:21(6):832–842. https: //doi.org/10.1016/S1470–2045(20)30110–8

The authors declare that there are no conflicts of interest present.